Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Payables (2016 - 2025)

Historic Payables for Ascendis Pharma A (ASND) over the last 10 years, with Q4 2025 value amounting to $605.4 million.

  • Ascendis Pharma A's Payables rose 215.47% to $605.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $605.4 million, marking a year-over-year increase of 215.47%. This contributed to the annual value of $587.7 million for FY2025, which is 83.3% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Payables of $605.4 million as of Q4 2025, which was up 215.47% from $863.5 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Payables ranged from a high of $863.5 million in Q3 2025 and a low of $53.2 million during Q2 2021
  • Moreover, its 5-year median value for Payables was $137.0 million (2023), whereas its average is $372.1 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 45940.09% in 2024, then tumbled by 429.32% in 2025.
  • Ascendis Pharma A's Payables (Quarter) stood at $76.0 million in 2021, then surged by 51.29% to $114.9 million in 2022, then surged by 369.59% to $539.8 million in 2023, then increased by 9.8% to $592.6 million in 2024, then grew by 2.15% to $605.4 million in 2025.
  • Its Payables stands at $605.4 million for Q4 2025, versus $863.5 million for Q3 2025 and $790.5 million for Q2 2025.